Plain-English translation of NCT07563322 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing nicotinamide riboside (a form of vitamin B3) in people with combined pulmonary hypertension—a serious condition where high pressure in the lung blood vessels strains the heart. Researchers believe this supplement may help cells produce energy more efficiently and improve how blood vessels and heart muscle function. The study will measure how the medication affects your body's biology and energy production at the cellular level.
Currently, there are no approved medications for combined pulmonary hypertension, and many patients develop serious heart problems. Computer analysis of patient biology suggested that this medication might help, so researchers want to carefully study how it affects the body's cellular energy and other biological markers in people with this condition.
You likely qualify if…
You likely don't qualify if…
You will take the medication (or placebo) on a schedule determined by the researchers, with study visits to have blood drawn and have biological measurements taken to see how the supplement affects your body's energy production and cellular health. The study involves a small group of carefully selected participants and focuses on understanding the biological effects rather than measuring symptom improvement. You should be prepared for regular clinic visits and blood tests over the course of the study.
AI-generated summary from trial data · Jul 7, 2026 · Not medical advice
United States